Article Sidebar

Submitted
December 25, 2023
Accepted
December 25, 2023
Published
December 25, 2023
Download
PDF
Statistic
Read Counter : 301 Download : 322

Main Article Content

Abstract

Background: The ABO and Rh system have a great association
to different kind of malignancy as mentioned in the literature.
The data about prevalence of blood group with thyroid
malignancies were limited in the literature; we aimed to record
the relationship of different ABO and Rh blood groups with
different malignant thyroid tumors.
Methodology: the demographics, ABO blood group, Rh factor,
histopathological type of malignant thyroid tumors were
recorded for each patient with malignant thyroid tumor (MTT);
then we evaluated the association between different blood group
types with different histopathological pattern.
Results: the commonest type of malignant thyroid carcinoma
was Papillary thyroid carcinoma (PTC) [n=46, (92%)], while all
other types were uncommon, they were follicular thyroid
carcinoma [(n=1) 2%], medullary thyroid carcinoma [(n=1) 2%],
Hürthle cell carcinoma [(n=1) 2%] and anaplastic thyroid
carcinoma [(n=1) 2%]., the blood group A with Rh positive was
the most frequent [n= 17, (34%)], , the O+ve was [n=15 (30%)],
B+ve [n=10 (20%)], while AB-ve [n=3 (6%)] while a small
number was Rhesus negative. The A+ve blood group was the
commonest blood group in PTC patients (34.8%), followed by
O+ve (30.4%).
Conclusion: Blood group A+ve is the most frequently reported
among cases of papillary thyroid carcinoma, which is the most
common MTT.

Article Details

License

Copyright (c) 2023 University of Thi-Qar Journal Of Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Wartofsky L, Van Nostrand D. Thyroid cancer: a comprehensive
  2. guide to clinical management: Springer; 2006.
  3. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for
  4. thyroid carcinoma: A population‐based study of 15,698 cases from the
  5. Surveillance, Epidemiology and End Results (SEER) Program 1973–1991.
  6. Cancer: Interdisciplinary International Journal of the American Cancer Society.
  7. ;79(3):564-73.
  8. Yang H, Yan J. A systematic review of prognosis of ABO blood
  9. group and rhesus factor on outcomes in patients with bladder cancer. Medicine.
  10. ;101(39):e30893.
  11. Wang J, García-Bailo B, Nielsen DE, El-Sohemy A. ABO
  12. genotype,‘blood-type’diet and cardiometabolic risk factors. PloS one.
  13. ;9(1):e84749.
  14. Liumbruno GM, Franchini M. Hemostasis, cancer, and ABO blood
  15. group: the most recent evidence of association. Journal of thrombosis and
  16. thrombolysis. 2014;38:160-6.
  17. Kim D-S, Scherer PE. Obesity, diabetes, and increased cancer
  18. progression. Diabetes & metabolism journal. 2021;45(6):799-812.
  19. Hovinga ICK, Koopmans M, de Heer E, Bruijn JA, Bajema IM.
  20. Change in blood group in systemic lupus erythematosus. The Lancet.
  21. ;369(9557):186-7.
  22. Edition S, Edge S, Byrd D. AJCC cancer staging manual. AJCC
  23. cancer staging manual. 2017.
  24. Lang TA, Secic M. How to report statistics in medicine: annotated
  25. guidelines for authors, editors, and reviewers: ACP Press; 2006.
  26. Habibzadeh F. Common statistical mistakes in manuscripts submitted
  27. to biomedical journals. European Science Editing. 2013;39(4):92-4.
  28. Habibzadeh F. Statistical data editing in scientific articles. Journal of
  29. Korean medical science. 2017;32(7):1072-6.
  30. Karhu D, Vanzieleghem M. Significance of digits in scientific
  31. research. AMWA J. 2013;28(2):58-60.
  32. Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain K,
  33. Bigos S, et al. The impact of age and gender on papillary thyroid cancer survival.
  34. The Journal of Clinical Endocrinology & Metabolism. 2012;97(6):E878-E87.
  35. Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity.
  36. Future Oncology. 2010;6(11):1771-9.
  37. Yager J, Leihr J. Molecular mechanisms of estrogen carcinogenesis.
  38. Annual review of pharmacology and toxicology. 1996;36(1):203-32.
  39. Lee M, Chen G, Vlantis A, Tse G, Leung B, Van Hasselt C. Induction
  40. of thyroid papillary carcinoma cell proliferation by estrogen is associated with an
  41. altered expression of Bcl-xL. The Cancer Journal. 2005;11(2):113-21.
  42. Zeng Q, Chen G, Vlantis A, Van Hasselt C. Oestrogen mediates the
  43. growth of human thyroid carcinoma cells via an oestrogen receptor–ERK
  44. pathway. Cell Proliferation. 2007;40(6):921-35.
  45. Ortega J, Sala C, Flor B, Lledo S. Efficacy and cost-effectiveness of
  46. the UltraCision® harmonic scalpel in thyroid surgery: an analysis of 200 cases in
  47. a randomized trial. Journal of Laparoendoscopic & Advanced Surgical
  48. Techniques. 2004;14(1):9-12.
  49. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated
  50. thyroid cancer in the United States, 1988–2005. Cancer: Interdisciplinary
  51. International Journal of the American Cancer Society. 2009;115(16):3801-7.
  52. Moysich KB, Menezes RJ, Michalek AM. Chernobyl-related ionising
  53. radiation exposure and cancer risk: an epidemiological review. The Lancet
  54. Oncology. 2002;3(5):269-79.
  55. Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch
  56. V, et al. Risk of thyroid cancer after exposure to 131 I in childhood. Journal of
  57. the National Cancer Institute. 2005;97(10):724-32.
  58. Parad MT, Fararouei M, Mirahmadizadeh AR, Afrashteh S. Thyroid
  59. cancer and its associated factors: A population‐based case‐control study.
  60. International Journal of Cancer. 2021;149(3):514-21.
  61. LeClair K, Bell KJ, Furuya-Kanamori L, Doi SA, Francis DO, Davies
  62. L. Evaluation of gender inequity in thyroid cancer diagnosis: differences by sex
  63. in US thyroid cancer incidence compared with a meta-analysis of subclinical
  64. thyroid cancer rates at autopsy. JAMA Internal Medicine. 2021;181(10):1351-8.
  65. Franceschi S, Boyle P, Maisonneuve P, La Vecchia C, Burt AD, Kerr
  66. DJ, et al. The epidemiology of thyroid carcinoma. Critical reviews in
  67. oncogenesis. 1993;4(1):25-52.
  68. Davies L, Welch HG. Increasing incidence of thyroid cancer in the
  69. United States, 1973-2002. Jama. 2006;295(18):2164-7.
  70. Zhu C, Zheng T, Kilfoy BA, Han X, Ma S, Ba Y, et al. A birth cohort
  71. analysis of the incidence of papillary thyroid cancer in the United States, 1973–
  72. Thyroid. 2009;19(10):1061-6.
  73. Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S,
  74. et al. SEER Cancer Statistics Review, 1975–2013. Bethesda, MD: National
  75. Cancer Institute; 2016. 2016.
  76. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. The
  77. Lancet. 2016;388(10061):2783-95.
  78. Bonnefond S, Davies TF. Thyroid cancer—risks and causes. JournalThyroid Cancer—Risks and Causes. 2014.
  79. Reid ME, Mohandas N, editors. Red blood cell blood group antigens:
  80. structure and function. Seminars in hematology; 2004: Elsevier.
  81. Tam AA, Özdemir D, Fakı S, Bilginer MC, Ersoy R, Çakır B. ABO
  82. blood groups, Rh factor, and thyroid cancer risk: to ‘B’or not to ‘B’. Endocrine
  83. research. 2020;45(2):137-46.
  84. Franchini M, Liumbruno GM. ABO blood group: old dogma, new
  85. perspectives. Clinical Chemistry and Laboratory Medicine (CCLM).
  86. ;51(8):1545-53.
  87. Edgren G, Hjalgrim H, Rostgaard K, Norda R, Wikman A, Melbye M,
  88. et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a
  89. cohort study. American journal of epidemiology. 2010;172(11):1280-5.
  90. Hakomori S-i. Antigen structure and genetic basis of histo-blood
  91. groups A, B and O: their changes associated with human cancer. Biochimica et
  92. Biophysica Acta (BBA)-General Subjects. 1999;1473(1):247-66.
  93. Zhang B-L, He N, Huang Y-B, Song F-J, Chen K-X. ABO blood
  94. groups and risk of cancer: a systematic review and meta-analysis. Asian Pacific
  95. Journal of Cancer Prevention. 2014;15(11):4643-50.
  96. Coussens LM, Werb Z. Inflammation and cancer. Nature.
  97. ;420(6917):860-7.
  98. Li C, Xu F, Huang Q, Han D, Zheng S, Wu W, et al. Nomograms for
  99. differentiated thyroid carcinoma patients based on the eighth AJCC staging and
  100. competing risks model. JNCI Cancer Spectrum. 2021;5(3):pkab038.
  101. Kakudo K, Tang W, Ito Y, Mori I, Nakamura Y, Miyauchi A.
  102. Papillary carcinoma of the thyroid in Japan: subclassification of common type
  103. and identification of low risk group. Journal of clinical pathology.
  104. ;57(10):1041-6